Newly Diagnosed Classical Hodgkin Lymphoma Treatment Study
Response directed therapy in high risk pediatric Hodgkin lymphoma with brentuximab added to standard therapy.
In order to participate you must meet the following criteria:
- Are between 2 and 22 years of age at the time of enrollment.
Have newly diagnosed, pathologically confirmed cHL meeting one of the following Ann Arbor stages:
- Stage IIB with bulk
- Stage IIIB
- Stage IVA
- Stage IVB
This is a partial list of elgibility requirements.